Citrin deficiency (CD) is a Mendelian disease entity due to biallelic mutations of *SLC25A13* gene. With 18 exons and 17 introns, this gene is localized to chromosome 7q21.3, and encodes citrin, the liver-type mitochondrial aspartate/glutamate carrier isoform 2 (AGC2)[@b1][@b2][@b3]. Citrin has proven to be a dimeric protein with the molecular weight of 147.7 ± 1.7 kDa, and has a three-domain structure: a calcium-regulated N-terminal domain (residues 1--319, 36 kDa) with eight EF-hand motifs, a mitochondrial carrier domain (residues 320--612, 32 kDa) with six transmembrane helices, and a C-terminal domain (residues 613--675, 6 kDa) with an amphipathic helix being involved in the calcium-dependent regulation of the opening and closing of the AGC2 vestibule[@b4].

Three age-dependent CD phenotypes have been described, which manifest in neonates or infants as neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD, OMIM \#605814)[@b5][@b6][@b7][@b8][@b9][@b10], in older children as failure to thrive and dyslipidemia caused by citrin deficiency (FTTDCD)[@b4][@b11][@b12][@b13][@b14][@b15], and in adolescents and adults, usually between the ages of 11 and 79 years, as adult-onset citrullinemia type II (CTLN2, OMIM \#603471)[@b1][@b8][@b9][@b16]. After the NICCD period, some individuals might directly step into FTTDCD and some could develop CTLN2 in one or more decades[@b5][@b17][@b18][@b19][@b20].

The *SLC25A13* genetic testing has been recognized as a reliable method for the definitive diagnosis of NICCD. However, about 10--15% of the *SLC25A13* mutations could not be detected by conventional DNA analysis[@b21][@b22], and the identification of these obscure mutations constitutes a challenge against the definite diagnosis of NICCD[@b23][@b24]. Although about 200 Chinese NICCD patients have been diagnosed via *SLC25A13* analysis to date[@b22][@b25][@b26][@b27], this number was rather limited, since China might have 85700 CD patients according to provisional epidemiological data[@b19][@b27][@b28]. Moreover, the *SLC25A13* mutations worldwide demonstrate remarkable heterogeneity[@b12][@b22][@b23][@b24][@b27][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38]. China is a vast country with a huge population, but the *SLC25A13* genotypic features of CD patients, including the mutation spectrum and their geographic distribution, remains far from being well clarified in our country.

In this study, besides the conventional DNA analyses, cDNA cloning and in silico prediction as well as functional analysis were carried out to definitely diagnose pediatric CD patients. In addition, we investigated the geographic distribution of the *SLC25A13* mutations and genotypes, and evaluated the allelic heterogeneity in an attempt to provide reliable evidences for the determination of relevant molecular diagnostic targets in different geographic areas of China.

Results
=======

New CD patients and the establishment of a large pediatric cohort
-----------------------------------------------------------------

As shown in [Table 1](#t1){ref-type="table"}, this study diagnosed 154 new CD patients via sophisticated molecular, functional and bioinformatic analysis. Along with the 120 cases reported previously[@b23][@b24][@b27][@b33][@b34], a large cohort with a total of 274 CD patients were established by our group from July, 2005 to the end of February, 2016. To the best of our knowledge, this is the largest CD cohort described in official references to date. This pediatric CD cohort encompassed 117 females and 157 males, and involved 264 families from 26 provinces, autonomous regions and municipalities in China ([Fig. 1](#f1){ref-type="fig"}).

Novel mutations and cDNA cloning analysis
-----------------------------------------

As shown in [Table 2](#t2){ref-type="table"}, 9 novel *SLC25A13* mutations were identified in this study, and among them, c.103A \> G (p.M35V), c.493C \> T (p.Q165X), c.755−1G \> C, c.845_c.848 + 1delG, c.933_c.933 + 1insGCAG, c.1381G \> T (p.E461X), c.1452 + 1G \> A and c.1706_1707delTA (p.S331fsX363) ([Fig. 2a](#f2){ref-type="fig"}) were detected by Sanger sequencing of all the 18 *SLC25A13* exons and their flanking sequences. To address the issue whether and how c.755−1G \> C, c.845_c.848 + 1delG and c.933_c.933 + 1insGCAG affect the splicing process of the relevant pre-mRNA molecules, cDNA cloning analysis of the transcripts from the affected *SLC25A13* alleles in PBLs were performed. They were found to give rise to the aberrant transcripts *r.*755_756delAG (p.252fs269X), *r.*845_848delG (p.D283fsX285) and *r.*933_934insGCAG (p.A312fsX317), respectively ([Fig. 2b](#f2){ref-type="fig"}).

In patient C0360, four high-frequency mutation screening just detected the maternal mutation IVS16ins3kb. Further cDNA cloning analysis revealed that all the transcripts from the paternal allele featured exon 5 skipping ([Table 3](#t3){ref-type="table"}). The following screening of large insertion/deletion with primer set located in the adjacent intronic regions of exon 5 revealed a paternally-inherited unexpected PCR band of 1 kb in size, as illustrated in [Fig. 3](#f3){ref-type="fig"}. Direct sequencing of this unexpected product revealed a 2646 bp deletion, involving the entire exon 5 and the adjacent intronic sequences, along with a 23 bp insertion 40 bp behind the breakpoint. According to the nomenclature rules[@b39][@b40], this complex mutation was described as \[c.329−154_c.468 + 2352del2646; c.468 + 2392_c.468 + 2393ins23\], predictively leading to the production of a truncated citrin molecule p.E110fs127X.

In patient C0388, the maternal *SLC25A13* allele harbored two mutations \[c.851_854del4; c.1452 + 1G \> A\], while the paternal mutation was not detected by direct DNA sequencing. The subsequent cDNA cloning analysis also shown that all the transcripts were from the maternal allele with *r.*851_854del4; moreover, half of them (12/21) demonstrated exon 14 skipping (*r*.1312_1452del, p.Ala438_Lys484del) ([Table 3](#t3){ref-type="table"}), indicating that the mutation c.1452 + 1G \> A affected the splicing process of pre-mRNA molecules transcribed from the maternal allele.

Bioinformatic and functional findings of the novel missense mutation c.103A \> G (p.M35V)
-----------------------------------------------------------------------------------------

Alignment analysis in 11 different species indicated that the amino acid M35 in citrin protein is highly conserved ([Supplemental Information 1](#S1){ref-type="supplementary-material"}). The probability value of disease-causing potential was \>0.9999 upon MutationTaster analysis and strongly indicated its deleterious nature. Meanwhile, this mutation is predicted to be probably damaging by using PolyPhen-2 with a score of 0.989 (sensitivity: 0.72; specificity: 0.97), and have a deleterious effect by using PROVEAN with a score of −3.25.

As depicted in [Fig. 4](#f4){ref-type="fig"}, after growing for 96 hours, the growth ability of the pYX212-mutant (p.M35V) was not significantly different (*P* = 0.341) from that of the empty vector pYX212 (vector). However, both of them had significantly lower (*P* = 0.000) growth ability in comparison to pYX212-citrin (citrin). These findings indicated that the mutation p.M35V, as a lack-of-function variation, caused the elimination of the AGC2 function of citrin protein.

*SLC25A13* mutation spectrum and regional distribution
------------------------------------------------------

*SLC25A13* mutations/variations were detected in 522 out of the 528 independent alleles in [Table 2](#t2){ref-type="table"}, with the diagnostic efficiency of 98.86%. The *SLC25A13* spectrum was composed of 41 mutations/variations, including 12 missense mutations, 8 deletion, 10 nonsense, 4 splice-site, 3 insertion, 1 duplication, 1 pathogenic SNP[@b29][@b41][@b42], 1 aberrant transcript[@b42] and 1 complex mutation. The variations c.851_854del4 (58.33%), c.1638_1660dup (8.52%), IVS6 + 5G \> A (7.58%) and IVS16ins3kb (10.04%) constituted the high-frequency mutations on top of the list. Three other mutations, IVS4ins6kb, IVS11 + 1G \> A and c.1399C \> T (p.R467X), were found at relative frequencies of 1--2%, and the remaining 34 mutations each had frequencies \<1%.

Among all the 41 mutations/variations, as shown in [Table 2](#t2){ref-type="table"}, 16 ones were detected in the north, 16 in the border and 27 in the south. Meanwhile, there were 6 private mutations in the north, 8 in the border and 15 in the south. The comparisons of their relative frequencies among the three areas revealed that c.775C \> T (p.Q259X), c.851_854del4, c.1078C \> T (p.R360X), IVS11 + 1G \> A, c.1364G \> T (p.R455L), c.1399C \> T (p.R467X) and IVS16ins3kb presented with significantly different geographic distribution with *P* all \<0.05 ([Table 2](#t2){ref-type="table"}). In pairwise comparisons, the southern population had a higher relative frequency of c.851_854del4 than the border (*P *=* *0.001) and northern (*P *=* *0.000) populations. By contrast, the relative frequency of IVS16ins3kb was lower in the south than in the border (*P *=* *0.013) and the north (*P *=* *0.005). Besides, when compared with the south region, the relative frequencies of c.1399C \> T (p.R467X) (*P *=* *0.003) in the border and those of c.1364G \> T (p.R455L) (*P *=* *0.012) and IVS11 + 1G \> A (*P *=* *0.015) in the north were higher. No significant difference were observed on the geographic distribution of the mutations IVS6 + 5G \> A and c.1638_1660dup among different areas.

*SLC25A13* genotype and allelic heterogeneity
---------------------------------------------

Except the 6 patients with only one mutation detected and the 13 ones with parents of different geographic origins, in this paper, the remaining 245 unrelated individuals were enrolled for the comparison of the genotype distribution. As shown in [Table 4](#t4){ref-type="table"}, there were 23 individuals from the north, 35 from the border and 187 from the south, respectively. Among a total of 53 genotypes, the four genotypes c.851_854del4/c.851_854del4, c.851_854del4/IVS16ins3kb, c.851_854del4/IVS6 + 5G \> A and c.851_854del4/c.1638_1660dup were dominant with the relative frequencies of 42.04%, 10.61%, 7.76% and 6.94%, respectively. Despite of the marked diversity of the genotypes, only c.851_854del4/c.851_854del4 and c.851_854del4/c.1399C \> T (p.R467X) demonstrated significantly different geographic distribution with *P* \< 0.05. Further pairwise comparisons revealed that the relative frequency of c.851_854del4/ c.851_854del4 in the south was much higher than that in the north (*P* = 0.000).

The observed homozygosity calculated based on the genotype frequencies was 17.39% (4/23) in the north, 34.28% (12/35) in the border and 52.94% (99/187) in the south, respectively. In addition, the theoretical homozygosity value, which was calculated based on allele frequencies, was 15.24% in the north, 24.31% in the border and 44.81% in the south, respectively. In pairwise comparisons, both of the observed and theoretical homozygosity values were higher in the south than in the north, with the *P* values of 0.001 and 0.012, respectively. In other words, the northern population had a higher level of allelic heterogeneity at the *SLC25A13* locus than the southern population.

Discussion
==========

The first case of NICCD in mainland China was reported by our group in 2006[@b43]. Since then, more and more Chinese CD patients were definitely diagnosed by *SLC25A13* genetic analysis in our department[@b23][@b24][@b27][@b33][@b34]. During this process, conventional DNA analytic approaches such as PCR/LA-PCR, PCR-RFLP and Sanger sequencing played important roles. In this study, as shown in [Table 2](#t2){ref-type="table"}, the four mutations c.851_854del4, c.1638_1660dup, IVS6 + 5G \> A and IVS16ins3kb together had a relative frequency of 84.47%, indicating that the screening of these high-frequency mutations should be initially performed for the rapid molecular diagnosis of CD patients. In addition, direct sequencing of the 18 *SLC25A13* exons and their adjacent intronic regions could identified the remaining micro mutations, which accounted for 12.5%. Besides, the functional and bioinformatic tools also made substantial contribution to the pathogenicity confirmation of the novel missense mutation c.103A \> G (p.M35V). As a result, the 154 new CD patients diagnosed in this paper, together with those reported in our department previously, constituted a 274-case cohort. So far as we know, this is the hitherto largest CD cohort in official references worldwide, laying a foundation for our subsequent clinical investigation. In particular, the 9 novel mutations identified in this study enriched the *SLC25A13* mutation spectrum, and provided reliable laboratory evidences not only for the definite diagnosis of the corresponding individuals, but also for the genetic counseling of their families in the future.

It was noteworthy that, as an unique technique developed by our group[@b42], the *SLC25A13* cDNA cloning analysis using PBLs had proved to be a feasible tool for the detection of the large insertion/deletion mutations[@b23][@b24][@b27]. In this paper, this molecular tool also played unique roles in the definite diagnosis of NICCD patients. The aberrant transcripts detected by cDNA analysis proved that c.755 − 1G \> C, c.845_c.848 + 1delG, c.933_c.933 + 1insGCAG and c.1452 + 1G \> A all had influence on the splicing process of the pre-mRNA. In addition, by using this tool, the novel mutation \[c.329 − 154_c.468 + 2352del2646; c.468 + 2392_c.468 + 2393ins23\] in patient C0360 was identified as the third large mutation resulting in exon 5 skipping (*r.*329_468, p.E110fs127X) following the mutation IVS4ins6kb (GenBank accession number: KF425758)[@b27] and c.329 − 1687_c.468 + 3865del[@b24]. Of particular note, in patient C0388, we confirmed that the maternally-inherited allele harbored two deleterious mutations based on the cDNA cloning results. Although the paternal mutation remained to be explored currently, the undetectable transcriptional product from the paternal allele clearly indicated the existence of a pathogenic mutation, providing direct laboratory evidences supporting the CD diagnosis. Unfortunately, due to the lack of fresh PBLs or liver specimens for further cDNA cloning analysis, mutations in 6 *SLC25A13* alleles remained obscure in this study; however, the rate of unidentified mutations (1.14% of all mutated alleles) in our study is much lower than those in previous publications using the conventional molecular approaches only. *SLC25A13* cDNA cloning analysis using PBLs should be taken as an important tool for the molecular diagnosis of CD patients.

Although the relative frequencies of c.1638_1660dup and IVS6 + 5G \> A were uniform in different regions of China, some *SLC25A13* mutations demonstrated different geographic distribution in this study. The relative frequencies of c.851_854del4 tended to decrease gradually from south to north, while that of IVS16ins3kb had an opposite tendency, as shown in the [Table 2](#t2){ref-type="table"}. The genetic variation following a continuous pattern from south to north might be attributed to the genetic flow occurred between distinct populations. Recent genetic studies have suggested that modern humans colonized East Asia via Southern and Northern routes on both sides of the Himalayas. Genetic flow between populations, which took place when the two migration routes overlapped, probably lasted a long time, resulting in the continuous pattern of genetic variation[@b44][@b45]. The continuous patterns of genetic variation at the *SLC25A13* locus in the present study are compatible with this presumed migration model. Actually, previous haplotype study[@b28] suggested that c.851_854del4 originated around the Guangxi and Yunan areas. Its higher frequency in south China can be explained as a result of the founder effect, while its lower frequency in the north, by genetic drift. Interestingly, besides the four common mutations, c.1399C \> T (p.R467X) was relatively common in the border, while IVS11 + 1G \> A and c.1364G \> T (p.R455L) were relatively common in the north. This phenomenon might be attributed to different founding populations but a lower migration rate among different areas in mainland China. These mutations should be considered as targets when establishing a screening strategy for CD patients in relevant populations.

Moreover, although a diversity of genotypes with a total number of 53 was discovered in the large CD cohort, c.851_854del4/c.851_854del4 was the unique genotype with higher relative frequency in the south than in the north (49.20% *vs* 4.35%), as shown in [Table 4](#t4){ref-type="table"}. This could be explained once again by the aforementioned founder effect of the c.851_854del4 mutation, which might occurred in a far remote ancestor in the south; Furthermore, subsequent homozygosity comparison demonstrated that, different from the CD patients from the south who had higher homozygosity, patients in the north showed higher allelic heterogeneity at the *SLC25A13* locus. This finding suggested that some CD patients might be missed while the CD prevalence be underestimated in the north, when the same high-frequency mutations as in the south were choosed as the molecular targets for the detection of CD patients and *SLC25A13* carriers in the north area. Therefore, the exploration of additional *SLC25A13* mutations should be regarded as an important issue in the north area in terms of CD molecular diagnosis and epidemic survey.

In summary, via sophisticated molecular, functional and in silico analysis of *SLC25A13* gene and its cDNA, this paper reported 154 new CD patients and identified 9 novel pathogenic mutations. The *SLC25A13* mutation spectrum in the hitherto largest CD cohort of 274 cases and their different geographic distribution formed a substantial contribution to the in-depth understanding of the genotypic feature of CD patients in China, and provided reliable evidences for the development of molecular diagnostic strategies in different Chinese areas.

Methods
=======

Subjects and Ethics
-------------------

This research enrolled a total of 274 CD patients diagnosed by our group in the past over 10 years, including 154 new CD cases which were diagnosed by sophisticated molecular, functional and bioinformatic analysis of *SLC25A13* gene and its cDNA, as described below, from February, 2013 to the end of February, 2016. Our study adheres to the ethical guidelines of the World Medical Association Declaration of Helsinki (WMADH 2008) and was approved by the Medical Ethical Committee of the First Affiliated Hospital, Jinan University. *SLC25A13* analyses were conducted with the written informed consents from the guardians of the patients.

*SLC25A13* Mutation Analysis
----------------------------

Genomic DNA of the patients suspected to have CD and their parents was extracted from EDTA-anticoagulant peripheral venous blood. The 4 high-frequency mutations c.851_854del4, c.1638_1660dup, IVS6 + 5G \> A and IVS16ins3kb were initially screened by using PCR/LA-PCR and PCR-RFLP, respectively. All the 18 *SLC25A13* exons and their adjacent intronic regions were amplified by PCR and analyzed by Sanger sequencing in patients with just one mutation was detected. Following that, if there was a *SLC25A13* mutation remained obscure, IVS4ins6kb, another large insertion with relative high frequency in Chinese, would be screened by LA-PCR as in our previous publications[@b27].

Reverse transcription-PCR (RT-PCR) and cDNA cloning analysis
------------------------------------------------------------

RT-PCR and cDNA cloning analysis were subsequently carried out in patients still with undetected mutation by all the approaches above, and in those with novel mutations that might affect the splicing of pre-mRNA molecules. In brief, total RNA was extracted from peripheral blood lymphocytes (PBLs), which were collected from 2 ml fresh EDTA-anticoagulant peripheral venous blood. Then RT-PCR was performed to synthesized cDNA following the kit manufacture's protocol (Invitrogen, USA). With the cDNA as template, nest-PCR was then performed for the target products, and the purified nest-PCR products were cloned into PMD-18T vector (Takara, Japan) and transformed into DH5α Escherichia coli competent cells. The positive clones were tested by LA-PCR with the universal primer set RVM (GAGCGGATAACAATTTCACACAGG) and M13-47 (CAGCACTGACCCTTTTGGGACCGC) and then sequenced, as previously described[@b42].

*In silico* analyses
--------------------

The conservative property of the amino acid affected by the novel missense mutation was analyzed by the software Clustal Omega (<http://www.ebi.ac.uk/Tools/msa/clustalo/>)[@b46]. The amino acid sequences of human citrin were comparatively aligned with other homologous proteins from 10 different eukaryotic species, including chimpanzee, mouse, rat, dog, cow, pig, opossum, chicken, xenopus tropicalis and caenorhabditis elegans. All of these amino acid sequences were obtained from the NCBI database ([www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)). Then the pathogenicity of the missense mutation was predicted by the softwares PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/>)[@b47][@b48], mutationTaster (<http://mutationtaster.org/> MutationTaster/index.html)[@b49] and PROVEAN (<http://provean.jcvi.org/index.php>)[@b50][@b51], respectively.

Functional study
----------------

A diploid AGC1-disrupted yeast model, BYagc1Δ, which was constructed in our previous publication[@b34], was used to evaluate the functional effect of the novel missense mutation. The normal citrin-coding sequence (NM_014251.2) was amplified and the novel missense mutation was introduced into the wild type *SLC25A13* cDNA by overlap-extension PCR. These products were purified and cloned into the vector pYX212 (Novagen, USA) to constitute the plasmid pYX212-citrin and pYX212-mutant, respectively. The BYagc1Δ strains were then transfected with the recombinant plasmids and the empty vector pYX212, respectively. The positive clones were screened using the uracil minus medium SD-URA and cultured in SA medium with acetate as the unique carbon source. After 96 hour of culture, the growth abilities of these three strains were assessed by the cell density measured at OD~600~.

Geographic division
-------------------

The Yangtze River has been considered as a historically significant boundary of the Chinese population[@b52][@b53][@b54]. In addition, the previously estimated carrier rate of *SLC25A13* mutations was 1/48 in the south but 1/940 in the north of this river[@b28]. Accordingly, the distribution of the mutations and genotypes in this study were compared among the north, border and south regions relevant to this boundary, based on the origin of the parents of each case. In this study, individuals in the north area referred to those from Beijing, Inner Mongolia, Shangdong, Shanxi, Shaanxi, Henan, Hebei, Liaoning, Jilin and Heilongjiang; in the border, from Shanghai, Jiangsu, Anhui, Hubei, Sichuan and Chongqing; and in the south, form Guangdong, Guangxi, Yunnan, Guizhou, Hunan, Fujian, Zhejiang, Jiangxi, Hainan and Taiwan, respectively.

Calculation of homozygosity
---------------------------

The theoretical homozygosity (J) at a locus in a given population is measured by J = ∑*Χ*~*i*~^2^, where ∑ stands for summation over all alleles, and *Χ*~*i*~ is the frequency of the *i*th allele[@b55][@b56]. If the number of the *i*th allele is m, *Χ*~*i*~ is calculated to be m/N, where N is the total number of the mutant alleles being investigated. The alleles harboring obscure mutations were counted as *SLC25A13* alleles different from those with detected variations, and thus, each of them was defined to have a frequency of 1/N.

Statistical analysis
--------------------

The frequencies of the *SLC25A13* mutations and genotypes, as well as the homozygosity values among the three geographic areas, were compared by means of Chi-square test or Fisher's exact tests, respectively. When the Chi-square test of 3 × 2 table was significant with *P* \< 0.05, pairwise comparisons were then performed with Bonferroni corrections of the *P* values. There were 3 pairwise comparisons: (1) north *vs* border, (2) north *vs* south, and (3) border *vs* south; accordingly, the adjusted *P* values of 2 × 2 Chi-square test for significance was 0.017 (0.05/3)[@b57]. The data of growth abilities of the yeast strains were analyzed by using one-way ANOVA followed by the Games-Howell test for the pairwise comparison of the non-homogeneity of variances, with *P* \< 0.05 as the significant criteria. All statistical calculations were performed on the software SPSS17.0.
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![Native places of the 274 Chinese patients with citrin deficiency.\
By the end of February in 2016, 274 Chinese patients from 26 provinces, municipalities and autonomous regions in China were diagnosed. This figure was generated by means of the software WPS Office PowerPoint 2016, which was freely available at <http://www.wps.cn/product/wps2016/>. The base map was created by incrementally assembling the outlines of the Chinese administrative regions, which could be downloaded via the URL link <http://www.pptstore.net/ppt_yuansu/12145.html>, as a free network resource.](srep29732-f1){#f1}

![Novel mutations and ASVs identified by direct DNA sequencing analysis and cDNA analysis.\
The figure (**a**) showed the segmental DNA sequencing results of the 8 novel micro mutations. The figure (**b**) illustrated the cDNA sequencing results of the aberrant transcripts *r.*845_848delG, *r.*755_756delAG and *r.*933_934insGCAG, respectively, which were transcribed from the mutated alleles harboring c.845_c.848 + 1delG (C0221), c.755 − 1G \> C (C0257) and c.933_c.933 + 1insGCAG (C0364), respectively.](srep29732-f2){#f2}

![Identification of the mutation \[c.329−154_468 + 2352del2646bp; c.468 + 2392_468 + 2393ins23bp\] in patient C0360.\
(**a**) High-frequency mutation screening revealed the maternally-inherited mutation IVS16ins3kb. (**b**) Electrophoresis of the LA-PCR products with the primers covering exon 5 revealed an unexpected band of 1162 bp in size, which was inherited from the father. **(c)** Sanger sequencing of the 1162 bp product uncovered a 2646 bp deletion (sequences in blue), which spanned the entire exon 5 (capitals) and partial sequences of the introns 4 and 5. Meanwhile, a 23 bp insertion (sequences in red) which was 40nt behind the breakpoint was also discovered. Underlined were the primers for LA-PCR screening.](srep29732-f3){#f3}

![Functional analysis of the novel missense mutation c.103A \> G (p.M35V).\
After growing for 96 hours, the growth ability of the yeast strain pYX212-mutant (p.M35V) was not significantly different (*P* = 0.341) from that transfected with the empty vector pYX212 (vector). However, both of them had significantly lower (*P* = 0.000) growth ability in comparison to pYX212-citrin (citrin), the yeast strain transfected with normal citrin recombinant. The results in each group were means ± SD of six repeated experiments.](srep29732-f4){#f4}

###### Molecular diagnosis of 154 new NICCD patients.

  No.    Patients   Gender            *SLC25A13* mutations            No.   Patients   Gender                                *SLC25A13*mutations
  ----- ---------- -------- ---------------------------------------- ----- ---------- -------- -------------------------------------------------------------------------------
  01      C0171      Male         c.851_854del4/ c.851_854del4        78     C0289      Male                              IVS16ins3kb/ IVS16ins3kb
  02      C0172      Male          c.851_854del4/c.1064G \> A         79     C0290      Male                            c.851_854del4/ c.851_854del4
  03      C0173     Female      c.550C \> T(p.R184X)/IVS4ins6kb       80     C0291     Female                       c.550C \> T(p.R184X)/ c.1638_1660dup
  04      C0174     Female        c.851_854del4/ c.851_854del4        81     C0293      Male                             IVS6 + 5G \> A/ IVS16ins3kb
  05      C0175     Female           c.495delA/IVS16ins3kb            82     C0294     Female                           c.851_854del4/ c.851_854del4
  06      C0176      Male         c.851_854del4/ c.851_854del4        83     C0297      Male                           c.1092_1095delT/ c.851_854del4
  07      C0177      Male         c.851_854del4/ c.851_854del4        84     C0298      Male                              c.851_854del4/IVS16ins3kb
  08      C0178     Female        c.851_854del4/ c.851_854del4        85     C0298S    Female                             c.851_854del4/IVS16ins3kb
  09      C0180     Female         c.1638_1660dup/IVS16ins3kb         86     C0299     Female                             c.851_854del4/IVS16ins3kb
  10      C0181      Male                 c.2T \> C/?                 87     C0301      Male                            c.851_854del4/ c.1638_1660dup
  11      C0182     Female        c.851_854del4/ c.851_854del4        88     C0303      Male                         c.851_854del4/c.1048G \> A(p.D350N)
  12      C0183     Female         c.851_854del4/IVS16ins3kb          89     C0306     Female                           c.851_854del4/ IVS6 + 5G \> A
  13      C0184     Female          c.851_854del4/IVS4ins6kb          90     C0307     Female                           c.851_854del4/ c.851_854del4
  14      C0185      Male         c.851_854del4/ c.851_854del4        91     C0310      Male                            c.851_854del4/ c.851_854del4
  15      C0189      Male        c.851_854del4/ IVS6 + 5G \> A        92     C0314     Female                           c.851_854del4/ c.851_854del4
  16      C0190     Female        c.851_854del4/ c.851_854del4        93     C0315      Male                            c.851_854del4/ c.851_854del4
  17      C0191     Female        c.851_854del4/ c.851_854del4        94     C0316     Female                            c.1638_1660dup/IVS16ins3kb
  18      C0192     Female         c.851_854del4/IVS16ins3kb          95     C0319      Male                            c.851_854del4/ c.851_854del4
  19      C0197     Female        c.851_854del4/IVS6 + 5G \> A        96     C0320      Male                            c.851_854del4/ c.851_854del4
  20      C0201      Male         c.851_854del4/ c.851_854del4        97     C0321      Male                            c.1638_1660dup/IVS6 + 5G \> A
  21      C0205      Male         c.851_854del4/ c.851_854del4        98     C0323      Male                            c.851_854del4/ c.851_854del4
  22      C0206      Male         c.851_854del4/ c.851_854del4        99     C0324      Male                            c.851_854del4/ c.851_854del4
  23      C0207      Male          c.851_854del4/ IVS16ins3kb         100    C0325     Female                           c.851_854del4/ c.851_854del4
  24      C0208      Male      c.851_854del4/c.775C \> T(p.Q259X)     101    C0327      Male                            c.851_854del4/ c.851_854del4
  25      C0209      Male        c.851_854del4/ c.1638_1660dup        102    C0335     Female                           c.851_854del4/ c.1638_1660dup
  26      C0211     Female        c.851_854del4/ c.851_854del4        103    C0336      Male                         c.851_854del4/c.955C \> T(p.R319X)
  27      C0212     Female        c.851_854del4/ c.851_854del4        104    C0337      Male                              c.851_854del4/IVS16ins3kb
  28      C0215     Female       c.851_854del4/ c.1638_1660dup        105    C0338     Female                             c.851_854del4/IVS16ins3kb
  29      C0216      Male         c.851_854del4/ c.851_854del4        106    C0339     Female                             c.851_854del4/IVS16ins3kb
  30      C0217      Male        c.851_854del4/ c.1638_1660dup        107    C0340     Female                           c.851_854del4/ c.851_854del4
  31      C0219     Female        c.851_854del4/ c.851_854del4        108    C0343      Male                            c.851_854del4/ c.851_854del4
  32      C0220     Female          c.851_854del4/IVS4ins6kb          109    C0344     Female                           c.851_854del4/ c.851_854del4
  33      C0221      Male     IVS11 + 1G \> A/c.845_c.848 + 1delG     110    C0345     Female                           c.851_854del4/ c.851_854del4
  34      C0222     Female        c.851_854del4/IVS6 + 5G \> A        111    C0347     Female                         c.1048G \> A(p.D350N)/IVS16ins3kb
  35      C0224     Female        c.851_854del4/ c.851_854del4        112    C0348      Male                            c.851_854del4/ c.851_854del4
  36      C0226      Male     c.851_854del4/ c.1078C \> T(p.R360X)    113    C0349      Male                              c.851_854del4/IVS16ins3kb
  37      C0227      Male          c.851_854del4/ IVS16ins3kb         114    C0350     Female                           c.851_854del4/IVS6 + 5G \> A
  38      C0229      Male        c.851_854del4/ c.1638_1660dup        115    C0351      Male                            c.851_854del4/ c.851_854del4
  39      C0234     Female        c.851_854del4/ c.851_854del4        116    C0352      Male                            c.851_854del4/ c.851_854del4
  40      C0235     Female       c.851_854del4/ c.1638_1660dup        117    C0354      Male                            c.1638_1660dup/IVS6 + 5G \> A
  41      C0236      Male      c.851_854del4/ c.103A \> G(p.M35V)     118    C0355      Male                           IVS11 + 1G \> A/ c.1638_1660dup
  42      C0237      Male     c.851_854del4/c.1078C \> T(p.R360X)     119    C0356     Female                       IVS6 + 5G \> A/c.1399C \> T(p.R467X)
  43      C0238      Male         c.851_854del4/ c.851_854del4        120    C0357     Female                           c.851_854del4/ c.851_854del4
  44      C0239     Female        c.851_854del4/ c.851_854del4        121    C0358     Female                           c.851_854del4/ IVS6 + 5G \> A
  45      C0240      Male       IVS6 + 5G \> A/ IVS11 + 1G \> A       122    C0359      Male                              c.851_854del4/IVS16ins3kb
  46      C0241      Male      c.1063C \> G(p.R355G)/ IVS16ins3kb     123    C0360      Male    IVS16ins3kb/\[c.329−154_c.468 + 2352del2646; c.468 + 2392_c.468 + 2393ins23\]
  47      C0242     Female        c.851_854del4/ c.851_854del4        124    C0361      Male                            c.851_854del4/ c.851_854del4
  48      C0243     Female       c.1638_1660dup/c.1638_1660dup        125    C0363      Male                            c.1638_1660dup/IVS6 + 5G \> A
  49      C0244      Male           IVS16ins3kb/IVS16ins3kb           126    C0364      Male                     c.933 + 1_c.933 + 2insCAGG/c.1706_1707delTA
  50      C0245     Female        c.851_854del4/ c.851_854del4        127    C0366      Male                              IVS16ins3kb/ IVS16ins3kb
  51      C0246      Male         c.851_854del4/ c.851_854del4        128    C0367      Male                         c.851_854del4/c.1048G \> A(p.D350N)
  52      C0247      Male         c.851_854del4/ c.851_854del4        129    C0368     Female                           c.851_854del4/c.1638_1660dup
  53      C0248     Female         c.851_854del4/IVS16ins3kb          130    C0369      Male                         c.851_854del4/c.550C \> T(p.R184X)
  54      C0249     Female    c.1638_1660dup/c.1381G \> T(p.E461X)    131    C0371     Female                            c.851_854del4/c.1399C \> T
  55      C0250      Male         c.851_854del4/ c.851_854del4        132    C0373      Male                              c.851_854del4/IVS16ins3kb
  56      C0251     Female      IVS11 + 1G \> A/ c.1638_1660dup       133    C0373S    Female                             c.851_854del4/IVS16ins3kb
  57      C0253     Female         c.1638_1660dup/IVS16ins3kb         134    C0375     Female                            IVS16ins3kb/ c.851_854del4
  58      C0253S    Female         c.1638_1660dup/IVS16ins3kb         135    C0376      Male                            c.851_854del4/ c.851_854del4
  59      C0257      Male      IVS7−1G \> C/c.1364G \> T(p.R455L)     136    C0377      Male                            c.851_854del4/ c.851_854del4
  60      C0258     Female       c.1638_1660dup/c.1638_1660dup        137    C0378      Male                            c.851_854del4/ c.851_854del4
  61      C0261      Male         c.851_854del4/ c.851_854del4        138    C0380      Male                            c.851_854del4/ c.851_854del4
  62      C0262      Male         c.851_854del4/ c.851_854del4        139    C0382      Male                              c.851_854del4/IVS4ins6kb
  63      C0264     Female   c.851_854del4/ c.1399C \> T (p. R467X)   140    C0383     Female                           c.1638_1660dup/c.1638_1660dup
  64      C0266      Male         c.851_854del4/IVS6 + 5G \> A        141    C0384      Male                             c.851_854del4/ IVS16ins3kb
  65      C0267     Female        c.851_854del4/IVS6 + 5G \> A        142    C0385      Male                             c.851_854del4/ IVS16ins3kb
  66      C0268      Male    c.851_854del4/ c.1399C \> T (p. R467X)   143    C0387      Male                              IVS6 + 5G \> A/IVS4ins6kb
  67      C0270      Male         c.851_854del4/ c.851_854del4        144    C0388     Female                       \[c.851_854del4; c.1452 + 1G \> A\]/?
  68      C0272     Female        c.851_854del4/ c.851_854del4        145    C0392     Female                           c.851_854del4/ c.851_854del4
  69      C0273      Male         c.851_854del4/ c.851_854del4        146    C0394      Male                             c.1638_1660dup/IVS16ins3kb
  70      C0276      Male         c.851_854del4/ c.851_854del4        147    C0395      Male                            c.851_854del4/ c.1638_1660dup
  71      C0277      Male         c.851_854del4/ c.851_854del4        148    C0396      Male                            IVS6 + 5G \> A/IVS6 + 5G \> A
  72      C0278     Female        c.851_854del4/ c.851_854del4        149    C0397     Female                           c.851_854del4/ IVS6 + 5G \> A
  73      C0280     Female        c.851_854del4/ c.851_854del4        150    C0398     Female                           c.851_854del4/ c.851_854del4
  74      C0283     Female        c.851_854del4/ c.851_854del4        151    C0400      Male                            c.851_854del4/ IVS6 + 5G \> A
  75      C0284      Male          IVS16ins3kb/IVS6 + 5G \> A         152    C0401     Female                             c.493C \> T/ IVS16ins3kb
  76      C0286      Male           IVS16ins3kb/ IVS16ins3kb          153    C0403     Female                           c.851_854del4/ c.851_854del4
  77      C0288      Male         c.851_854del4/IVS6 + 5G \> A        154    C0404      Male                              IVS4ins6kb/ c.851_854del4

###### Spectrum of the *SLC25A13* mutation/variations identified in the CD patients and their relative frequency.

  No.    Location                                    Systematic name (DNA level)                                      Amino acids                         Types                        Relative frequency (%)    *P*                      
  ----- ---------- ----------------------------------------------------------------------------------------------- ----------------- ------------------------------------------------ ------------------------ -------- -------- -------- -------
  01       Ex1                                                c.2T \> C                                             p.Met1_Phe34del     Pathogenic SNP[※](#t2-fn2){ref-type="fn"}               0.00             0.00     0.77     0.57    1.000
  02      Ex2_3                                             *r*.16-212dup                                               Unclear       Aberrant transcript[▲](#t2-fn3){ref-type="fn"}            0.00             0.00     0.26     0.19    1.000
  03       Ex3                                               c.72T \> A                                                 p.Y24X                           Nonsense                               0.00             1.23     0.00     0.19    0.258
  04       Ex3                                 c.103A \> G[\*](#t2-fn1){ref-type="fn"}                                  p.M35V                           Missense                               0.00             0.00     0.26     0.19    1.000
  05       Ex4                                                c.265delG                                               p.D89fs94X                         Deletion                               0.00             0.00     0.26     0.19    1.000
  06       Ex5                                       c.329−1687_c.468 + 3865del                                      p.E110fs127X                        Deletion                               0.00             0.00     0.26     0.19    1.000
  07       Ex5      \[c.329−154_c.468 + 2352del2646; c.468 + 2392_c.468 + 2393ins23\][\*](#t2-fn1){ref-type="fn"}    p.E110fs127X                        Complex                                0.00             1.23     0.00     0.19    0.258
  08       Ex5                                               IVS4ins6kb                                              p.E110fs127X                       Insertion                               1.82             2.47     1.28     1.52    0.310
  09       Ex6                                               c.475C \> T                                                p.Q159X                          Nonsense                               0.00             1.23     0.00     0.19    0.258
  10       Ex6                                 c.493C \> T[\*](#t2-fn1){ref-type="fn"}                                  p.Q165X                          Nonsense                               0.00             1.23     0.00     0.19    0.258
  11       Ex6                                                c.495delA                                              p.Q165fs195X                        Deletion                               0.00             1.23     0.00     0.19    0.258
  12       Ex6                                               c.550C \> T                                                p.R184X                          Nonsense                               0.00             1.23     0.51     0.57    0.592
  13       IVS6                                            IVS6 + 5G \> A                                            P.V260fs212X                      Splice-site                              3.64             8.64     7.91     7.58    0.494
  14       Ex7                                               c.754G \> A                                                p.E252K                        Splice-site                              1.82             0.00     0.26     0.38    0.221
  15       IVS7                               c.755−1G \> C[\*](#t2-fn1){ref-type="fn"}                               p.252fs269X                        Deletion                               1.82             0.00     0.00     0.19    0.104
  16       Ex8                                               c.775C \> T                                                p.Q259X                          Nonsense                               0.00             2.47     0.00     0.38    0.034
  17       Ex8                                               c.790G \> A                                                p.V264I                          Missense                               0.00             0.00     0.26     0.19    1.000
  18       Ex8                                               c.847G \> T                                                p.G283X                          Nonsense                               0.00             0.00     0.26     0.19    1.000
  19       Ex8                             c.845_c.848 + 1delG[\*](#t2-fn1){ref-type="fn"}                           p.D283fsX285                        Deletion                               0.00             0.00     0.26     0.19    1.000
  20       Ex9                                              c.851_854del4                                            p.R284fs286X                        Deletion                              27.27            44.44    65.56    58.33    0.000
  21       Ex9                           c.933_c.933 + 1insGCAG[\*](#t2-fn1){ref-type="fn"}                          p.A312fsX317                       Insertion                               1.82             0.00     0.00     0.19    0.104
  22       Ex10                                              c.955C \> T                                                p.R319X                          Nonsense                               3.64             0.00     0.51     0.76    0.090
  23       Ex10                                              c.998G \> A                                                p.G333D                          Missense                               0.00             0.00     0.26     0.19    1.000
  24       Ex11                                         c.1019_1177 + 893del                                         p.340_392del                        Deletion                               1.82             0.00     0.00     0.19    0.104
  25       Ex11                                             c.1048G \> A                                                p.D350N                          Missense                               0.00             0.00     1.02     0.76    1.000
  26       Ex11                                             c.1063C \> G                                                p.R355G                          Missense                               0.00             0.00     0.51     0.38    1.000
  27       Ex11                                             c.1064G \> A                                                p.R355Q                          Missense                               0.00             0.00     0.51     0.38    1.000
  28       Ex11                                             c.1078C \> T                                                p.R360X                          Nonsense                               3.64             0.00     0.26     0.57    0.041
  29       Ex11                                            c.1092_1095delT                                           p.F365fs407X                        Deletion                               1.82             0.00     0.51     0.57    0.337
  30      IVS11                                            IVS11 + 1G \> A                                           p.340_392del                      Splice-site                              5.45             2.47     0.51     1.33    0.008
  31       Ex12                                             c.1215G \> T                                                p.K405N                          Missense                               1.82             0.00     0.00     0.19    0.104
  32       Ex13                                             c.1231G \> A                                                p.V411M                          Missense                               0.00             0.00     0.26     0.19    1.000
  33       Ex14                                             c.1364G \> T                                                p.R455L                          Missense                               3.64             0.00     0.00     0.38    0.008
  34       Ex14                               c.1381G \> T[\*](#t2-fn1){ref-type="fn"}                                  p.E461X                          Nonsense                               1.82             0.00     0.00     0.19    0.104
  35       Ex14                                             c.1399C \> T                                                p.R467X                          Nonsense                               0.00             6.17     0.77     1.52    0.007
  36       Ex14                             c.1452 + 1G \> A[\*](#t2-fn1){ref-type="fn"}                            p.A438_K484del                     Splice-site                              0.00             0.00     0.26     0.19    1.000
  37       Ex16                                             c.1622C \> A                                                p.A541D                          Missense                               0.00             1.23     0.00     0.19    0.258
  38       Ex16                                            c.1638_1660dup                                            p.A554fs570X                      Duplication                             16.36             7.41     7.65     8.52    0.089
  39       Ex16                             c.1706_1707delTA[\*](#t2-fn1){ref-type="fn"}                             p.S331fsX363                        Deletion                               0.00             1.23     0.00     0.19    0.258
  40      IVS16                                              IVS16ins3kb                                             p.A584fs585X                       Insertion                              20.00            16.05     7.40    10.04    0.002
  41       Ex17                                            c\. 1775A \> C                                               p.Q592P                          Missense                               0.00             0.00     0.26     0.19    1.000
  42                                                           Unknown                                                                                                                          1.82             0.00     1.28     1.14    0.478
                                                                Total                                                                                                                          100.00           100.00   100.00   100.00      

^\*^Novel mutations. The *P* value is for the comparison of the relative frequencies among three different areas.

^※^Reported in the refs [@b29],[@b41] and [@b42].

^▲^Identified in ref. [@b42].

###### The *SLC25A13* ASVs detected by cDNA cloning analysis in patients C0360 and C0388.

  Patients    No.  ASVs                                                                      Annotations                                                            Clones
  ---------- ----- ------------------------------------------------------------------------- --------------------------------------------------------------------- --------
  C0360        1   *r.*213_468del                                                            Exon 4, 5 skipping                                                       15
               2   *r.*213_468del; *r.*616_754del                                            Exon 4, 5, 7 skipping                                                    1
               3   *r.*213_468del; *r*.1453_1591del                                          Exon 4, 5, 15 skipping                                                   3
               4   *r.*70_468del                                                             Exon 3, 4, 5 skipping                                                    1
               5   *r*.69_70ins69 + 12147_69 + 12282; *r.*213_468del                         Exon 4, 5 skipping with partial intron 2 retention                       1
               6   *r.*328_468del                                                            Exon 5 skipping                                                          2
               7   *r.*328_468del; *r.*755_848del                                            Exon 5, 8 skipping                                                       1
                                                                                             Total                                                                    24
  C0388        1   *r.*213_328del, *r*.851_854del                                            Exon 4 skipping, *r*.851_854del                                          2
               2   *r.*213_328del, *r*.851_854del, *r*.1230_1231ins1230 + 1323_1230 + 1346   Exon 4 skipping, *r.*851_854del with partial intron 12 retention         1
               3   *r.*213_328del, *r*.616\_ 754del, *r*.851_854del                          Exon 4, 7 skipping, *r.*851_854del                                       1
               4   *r.*213_328del, *r*.616\_ 848del, *r*.851_854del, *r*.993_1018del         Exon 4, 7, 8 skipping, *r*.851_854del with partial exon 10 deletion      1
               5   *r.*213_328del, *r.*755_848del, *r*.851_854del                            Exon 4, 8 skipping, *r*.851_854del                                       3
               6   *r*.616_625del, *r.*755_848del, *r*.851_854del                            Exon 8 skipping, *r*.851_854del with partial exon 7 deletion             1
               7   *r.*213_328del, *r*.851_854del, *r*.1312_1452del                          Exon 4, 14 skipping, *r*.851_854del                                      3
               8   *r.*213_328del, *r.*755_848del, *r*.851_854del, *r*.1312_1452del          Exon4, 8, 14 skipping, *r*.851_854del                                    4
               9   *r.*213_468del, *r.*755_848del, *r*.851_854del, *r.*1312_1452del          Exon 4, 5, 8, 14 skipping, *r*.851_854del                                1
              10   *r.*213_328del, *r.*755_933del, *r*.1312_1452del                          Exon4, 8,,9, 14 skipping                                                 3
              11   *r.*213_328del, *r*.851_854del, *r*.1312_1591del, *r*.851_854del          Exon 4, 8, 14, 15 skipping, *r*.851_854del                               1
                                                                                             Total                                                                    21

ASVs: alternative splicing variants. In patient C0360, the ASVs from the maternal *SLC25A13* allele were not detected due to the mutation IVS16ins3kb, and thus all 24 detected ASVs in this patient had paternal origin, all featuring exon 5 skipping. In patient C0388, all 21 ASVs were from the maternal *SLC25A13* allele harboring mutation \[c.851_854del4; c.1452 + 1G \> A\], while those from the paternally-inherited allele with obscure mutation were not detected.

###### Comparison of the *SLC25A13* genotypes of the CD patients from different areas in China.

  NO.   Genotype                                                                         Relative frequency (%)    *P*                      
  ----- ------------------------------------------------------------------------------- ------------------------ -------- -------- -------- --------
  01    c.851_854del4/c.851_854del4                                                               4.35            28.57    49.20    42.04    0.000
  02    c.1638_1660dup/c.1638_1660dup                                                             4.35             2.86     1.60     2.04    0.339
  03    IVS6 + 5G \> A/IVS6 + 5G \> A                                                             0.00             0.00     0.53     0.41    1.000
  04    IVS16ins3kb/IVS16ins3kb                                                                   8.70             2.86     1.60     2.45    0.095
  05    c.851_854del4/c.1638_1660dup                                                              8.70             0.00     8.02     6.94    0.190
  06    c.851_854del4/IVS6 + 5G \> A                                                              0.00             5.71     9.09     7.76    0.374
  07    c.851_854del4/IVS16ins3kb                                                                21.74            14.29     8.56    10.61    0.083
  08    c.851_854del4/c.103A \> G (p.M35V)                                                        0.00             0.00     0.53     0.41    1.000
  09    c.851_854del4/IVS4ins6kb                                                                  4.35             0.00     1.60     1.63    0.407
  10    c.851_854del4/c.329−1687_c.468 + 3865del                                                  0.00             0.00     0.53     0.41    1.000
  11    c.851_854del4/c.550C \> T (p.R184X)                                                       0.00             0.00     0.53     0.41    1.000
  12    c.851_854del4/c.775C \> T (p.Q259X)                                                       0.00             2.86     0.00     0.41    0.237
  13    c.851_854del4/c.847G \> T (p.G283X)                                                       0.00             0.00     0.53     0.41    1.000
  14    c.851_854del4/c.955G \> A (p.R319X)                                                       4.35             0.00     0.00     0.41    0.094
  15    c.851_854del4/c.998G \> A (p.G333D)                                                       0.00             0.00     0.53     0.41    1.000
  16    c.851_854del4/c.1019_1177 + 893del                                                        4.35             0.00     0.00     0.41    0.094
  17    c.851_854del4/c.1048G \> A (p.D350N)                                                      0.00             0.00     1.07     0.82    1.000
  18    IVS6 + 5G \> A/c.1064G \> A (p.R355Q)                                                     0.00             0.00     1.07     0.82    1.000
  19    c.851_854del4/c.1078C \> T (p.R360X)                                                      0.00             0.00     0.53     0.41    1.000
  20    c.851_854del4/c.1092_1095delT                                                             0.00             0.00     0.53     0.41    1.000
  21    c.851_854del4/c.1215G \> T (p.K405N)                                                      4.35             0.00     0.00     0.41    0.0.94
  22    c.851_854del4/c.1231G \> A (p.V411M)                                                      0.00             0.00     0.53     0.41    1.000
  23    c.851_854del4/c.1399C \> T (p.R467X)                                                      0.00             8.57     1.07     2.04    0.032
  24    c.851_854del4/c.1775A \> C (p.Q592P)                                                      0.00             0.00     0.53     0.41    1.000
  25    c.1638_1660dup/IVS6 + 5G \> A                                                             0.00             2.86     2.14     2.04    0.744
  26    c.1638_1660dup/IVS16ins3kb                                                                4.35             2.86     1.60     2.04    0.339
  27    c.1638_1660dup/c.550C \> T (p.R184X)                                                      0.00             2.86     0.00     0.41    0.238
  28    c.1638_1660dup/c.265delG                                                                  0.00             0.00     0.53     0.41    1.000
  29    c.1638_1660dup/c.1063C \> G (p.R355G)                                                     0.00             0.00     0.53     0.41    1.000
  30    c.1638_1660dup/IVS11 + 1G \> A                                                            4.35             0.00     0.00     0.41    0.094
  31    c.1638_1660dup/c.1364G \> T (p.R455L)                                                     4.35             0.00     0.00     0.41    0.094
  32    c.1638_1660dup/c.1381G \> T (p.E461X)                                                     4.35             0.00     0.00     0.41    0.094
  33    IVS6 + 5G \> A/IVS16ins3kb                                                                0.00             2.86     1.07     1.22    0.557
  34    IVS6 + 5G \> A/c.955G \> A (p.R319X)                                                      4.35             0.00     1.07     1.22    0.306
  35    IVS6 + 5G \> A/IVS11 + 1G \> A                                                            0.00             2.86     0.00     0.41    0.237
  36    IVS6 + 5G \> A/c.1399C \> T (p.R467X)                                                     0.00             0.00     0.53     0.41    1.000
  37    IVS6 + 5G \> A/IVS4ins6kb                                                                 0.00             2.86     0.00     0.41    0.237
  38    IVS16ins3kb/\[c.329−154_c.468 + 2352del2646; c.468 + 2392_c.468 + 2393ins23\]             0.00             2.86     0.00     0.41    0.237
  39    IVS16ins3kb/IVS11 + 1G \> A                                                               4.35             0.00     0.00     0.41    0.094
  40    IVS16ins3kb/c.495delA                                                                     0.00             2.86     0.00     0.41    0.237
  41    IVS16ins3kb/c.1048G \> A (p.D350N)                                                        0.00             0.00     1.07     0.82    1.000
  42    IVS16ins3kb/c.1063C \> G (p.R355G)                                                        0.00             0.00     0.53     0.41    1.000
  43    IVS16ins3kb/c.493C \> T (p.Q165X)                                                         0.00             2.86     0.00     0.41    0.237
  44    g.2T \> C/r.16_212dup                                                                     0.00             0.00     0.53     0.41    1.000
  45    c.2T \> C/c.790G \> A (p.V264I)                                                           0.00             0.00     0.53     0.41    1.000
  46    IVS11 + 1G \> A/c.845_c.848 + 1delG                                                       0.00             0.00     0.53     0.41    1.000
  47    IVS11 + 1G \> A/c.1078C \> T (p.R360X)                                                    4.35             0.00     0.00     0.41    0.094
  48    c.550C \> T (p.R184X)/IVS4ins6kb                                                          0.00             0.00     0.53     0.41    1.000
  49    c.1399C \> T (p.R467X)/IVS4ins6kb                                                         0.00             2.86     0.00     0.41    0.237
  50    1092-1095delT/c.754G \> A                                                                 0.00             0.00     0.53     0.41    1.000
  51    c.475C \> T (p.Q159X)/c.1399C \> T (p.R467X)                                              0.00             2.86     0.00     0.41    0.237
  52    IVS7-1G \> C/c.1364G \> T (p.R455L)                                                       4.35             0.00     0.00     0.41    0.094
  53    c.775C \> T (p.Q259X)/c.72T \> A (p.Y24X)                                                 0.00             2.86     0.00     0.41    0.237
        Total                                                                                    100.00           100.00   100.00   100.00      

The *P* value is for the comparison of the relative frequencies among the three different areas.
